Skip to content

Trial Summary

A first in human Phase 1/2 open-label, multicenter, dose escalation and expansion study of PRS-344/S095012 in patients with solid tumors



ACTRN/NCT /ethics:


Scientific title:

A study of PRS-344/S095012 (PD-L1x4-1BB bispecific antibody) in patients with solid tumors

Sponsor / Cooperative group:

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
Tumour Stream -
Cancer StageAll stages
Anticipated Start Date2021-09-08
Anticipated End Date2024-11-15

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Phone08 8222 6140
Principal InvestigatorDr Timothy Price
Recruitment StatusRecruiting